CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Up 26.2% in December

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 5,540,000 shares, a growth of 26.2% from the November 30th total of 4,390,000 shares. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is currently 4.8 days.

CytomX Therapeutics Price Performance

NASDAQ CTMX traded up $0.01 on Tuesday, hitting $1.03. 809,626 shares of the company's stock were exchanged, compared to its average volume of 2,406,578. The firm has a market cap of $80.61 million, a price-to-earnings ratio of 6.06 and a beta of 1.07. The firm's 50-day moving average price is $1.05 and its two-hundred day moving average price is $1.18. CytomX Therapeutics has a fifty-two week low of $0.83 and a fifty-two week high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The firm had revenue of $33.43 million for the quarter, compared to analyst estimates of $18.92 million. During the same quarter in the prior year, the company posted $0.04 earnings per share. On average, research analysts predict that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a "neutral" rating on shares of CytomX Therapeutics in a research note on Monday, November 11th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $5.77.

Hedge Funds Weigh In On CytomX Therapeutics

Large investors have recently made changes to their positions in the stock. US Bancorp DE acquired a new position in CytomX Therapeutics during the third quarter worth $40,000. XTX Topco Ltd raised its stake in shares of CytomX Therapeutics by 382.6% during the 2nd quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company's stock worth $74,000 after buying an additional 48,033 shares during the last quarter. Forefront Analytics LLC raised its stake in shares of CytomX Therapeutics by 206.7% during the 2nd quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company's stock worth $78,000 after buying an additional 43,176 shares during the last quarter. Cubist Systematic Strategies LLC boosted its position in shares of CytomX Therapeutics by 96.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company's stock worth $100,000 after buying an additional 40,309 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in CytomX Therapeutics in the 3rd quarter valued at about $104,000. Hedge funds and other institutional investors own 67.77% of the company's stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.